Drug overdose is the leading cause of accidental death in the U.S., with opioid addiction driving this epidemic, including more than 20,000 overdose deaths related to prescription pain relievers in 20151. While opioids have typically been used for the management of orthopaedic postsurgical pain, EXPAREL provides targeted, non-opioid pain control by working right at the site of surgery, allowing for long-lasting pain relief. Reduced pain allows the opportunity for earlier weight bearing and mobilization immediately following surgery, and more patients discharged to home rather than interim care facilities.
"There are millions of orthopedic procedures performed in the U.S. market today where we can improve patient care and the surgical experience by offering a long acting, intra-operatively delivered local anesthetic infiltration solution," said Juan-José Gonzalez, President, DePuy Synthes U.S. "As part of our focused approach to help bring value at every point along the care pathway, we are thrilled to be able to further our offerings through partnering with Pacira and together provide a differentiated solution for our customers to help improve patient outcomes."
DePuy Synthes has extensive reach in the orthopaedics and spine space, positioning the company to bring EXPAREL to joint reconstruction, spine, sports medicine, and trauma patients in the U.S. for in-hospital and outpatient procedures. Our suite of products and solutions help to drive improved clinical outcomes, reduced complication rates and improved recovery time.
DePuy Synthes is expected to begin co-promoting EXPAREL in Q1 2017.
EXPAREL® is a long acting local anesthetic indicated for single-dose infiltration into the surgical site to produce post-surgical analgesia. The U.S. Food and Drug Administration (FDA) confirmed that EXPAREL has been approved for administration into the surgical site to produce postsurgical analgesia in a variety of surgeries.2
About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Family of Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to an exclusive agreement in the U.S. with Pacira Pharmaceuticals Inc. to co-promote EXPAREL®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes Sales Inc., the DePuy Synthes Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the transaction may not be realized or may take longer to realize than expected; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; the ability of DePuy Synthes to successfully execute strategic plans...
drugs June 17, 2019
contractpharma January 18, 2017
contractpharma January 18, 2017
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
(All Rights Reserved)